Everpar Advisors LLC Makes New $782,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Everpar Advisors LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 890 shares of the biopharmaceutical company’s stock, valued at approximately $782,000.

Other hedge funds have also added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after acquiring an additional 669,517 shares in the last quarter. International Assets Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after acquiring an additional 590,314 shares in the last quarter. abrdn plc increased its holdings in shares of Regeneron Pharmaceuticals by 552.8% during the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after acquiring an additional 186,215 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Regeneron Pharmaceuticals by 129.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock valued at $190,170,000 after acquiring an additional 122,103 shares in the last quarter. Finally, National Bank of Canada FI increased its holdings in shares of Regeneron Pharmaceuticals by 161.8% during the fourth quarter. National Bank of Canada FI now owns 116,227 shares of the biopharmaceutical company’s stock valued at $105,185,000 after acquiring an additional 71,838 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on REGN. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Bank of America upped their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Finally, Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $981.71.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $11.33 during trading on Tuesday, reaching $969.97. 362,317 shares of the stock traded hands, compared to its average volume of 496,674. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company has a 50-day moving average of $942.67 and a 200-day moving average of $899.44. The stock has a market capitalization of $106.46 billion, a P/E ratio of 28.65, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the company posted $10.96 EPS. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $967.50, for a total value of $346,365.00. Following the transaction, the executive vice president now directly owns 13,431 shares in the company, valued at approximately $12,994,492.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,095 shares of company stock worth $8,729,766. 8.83% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.